Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Les indicacions geogràfiques protegeixen el nom d’un producte originari d’una zona geogràfica, a la qual li deu una determinada qualitat, reputació o una altra característica. Descobreix què són, en què consisteix el seu procediment de registre i quins beneficis atorguen.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
305
resultados
Última actualización
14/07/2026 [08:22:00]
Resultados 75 a 100 de 305
Resumen de: WO2020168254A1
A method of determining the potency of an immune cell is described. The method includes the steps of contacting an immune cell with an effective amount of a cell exosome and detecting the amount of a cytokine produced by the immune cell. Kits for assaying immune cell potency are also described. Potency assays are important for satisfying the FDA requirements for new biological agents, such as immunotherapeutic cells. Methods of using potent immune cells as an immunotherapeutic treatment are described.
Resumen de: US2025123294A1
In one aspect, a method for screening an individual for head and neck cancer, which comprising: acquiring a saliva sample from the individual, analyzing the saliva sample to detect one or more of HPVs and at least one of a phenotypic biomarker, a regulatory biomarker, a microbiome-derived biomarker, and a metabolomic biomarker dysregulated due to HPV infection, wherein detection of both of the HPV and at least one of said biomarkers indicates the individual is at risk of head and neck cancer.
Resumen de: WO2024227045A1
The present disclosure provides methods and kits for identifying and treating individuals at risk of or suffering from disease such as a neurological condition or disease. In general, detection or measurement of one or more biomarkers, such as neurofilament light chain (NfL), and combinations thereof with assays of the present disclosure, assists in the identification of disease such as neurological disease. The present disclosure also provides methods for selecting patients for treatment of neurological disease.
Resumen de: WO2024235880A1
The invention relates to an in vitro method for diagnosing or predicting a neurodegenerative disease in a subject, said method comprising A/T/N classification in nasal secretion samples obtained from said subject. Said A/T/N classification subsequently may be used, but is not limited to, the diagnosis of Alzheimer's disease (AD), the diagnosis of SNAP or the exclusion of AD.
Resumen de: WO2025038979A1
Material compositions and/or methods useful for the prophylaxis and/or treatment of protein depletion (proteinopenia) are provided, including material compositions that retains native function of a peptide/protein while limiting and/or preventing amyloid formation and/or aggregation of said peptide/protein. Material compositions and formulations for enhancing peptide/protein solubility, stability, circulation time, receptor interaction, brain penetrance, CSF half-life, facilitating peptide/protein synthesis and purification are also provided.
Resumen de: GB2702871A
Automatically validating quality data of at least a digital slide 110, 118 scanned by an optical device. The slide is identified 122 with metadata 120 and object detection 128 locates the stained core. The data from the stained core is aligned into a standard form 132 and evaluated against a threshold 134. The stained core is compared to a control core 136 to generate the validation output 138 which is transmitted to a downstream device 140. Generating the validation output may use a stain statistical model 142 to compute the threshold value and may include cross validating 170 a positive control core 164 to confirm. Further a reliability of the validation output may be obtained. This requires configuring one or more optical device parameters comprising a magnification level and a scanning speed of the optical device as a function of the stained core of interest and the positive control core. Figure 1
Resumen de: CN122249712A
本申请涉及高灵敏的免疫检测方法及系统。提供了一种高灵敏度目标蛋白的免疫检测方法，包括：捕获目标蛋白，得到含有免疫复合物的溶液；在无动力装置的作用下将含有免疫复合物的溶液平铺至检测载体；将免疫复合物固定在至少一个面上；以及检测并计算免疫复合物的浓度。本公开的免疫检测方法的使用结构简单、成本低的耗材结构，实现了高灵敏度的检测待测目标蛋白。
Resumen de: WO2025062119A2
The invention relates to a compound of formula I, wherein: A, B, R1, R2, L1, m and n are as defined in the specification, or a salt or solvate thereof, which compounds are useful for forming Raman-tagged bioconjugates with a biomarker and/or biomolecule and are detectable with Raman spectroscopy
Resumen de: WO2024213092A1
The present invention relates to protein markers relevant to mild cognitive impairment (MCI) and Alzheimer's disease (AD), especially those detectable in blood samples. Thus, methods and compositions are provided for risk assessment and early diagnosis of MCI and AD based on the analysis of these protein markers. Further provided are methods and compositions useful for evaluating the efficacy of a therapy for MCI or AD.
Resumen de: CN120142636A
The invention relates to prediction of post-stroke intestinal butyrate production microbiota and intestinal butyrate level on a post-stroke cognitive function and application of the post-stroke intestinal butyrate production microbiota and the intestinal butyrate level. Experimental research shows that the butyrate and/or the butyrate-producing flora can be used as a marker for predicting the cognitive function after the cerebral apoplexy, and the cognitive function after the cerebral apoplexy can be predicted by detecting the intestinal butyrate level after the cerebral apoplexy and/or the abundance of the butyrate-producing flora.
Resumen de: WO2026126161A2
Provided herein are methods and assays for detecting MTBR-243 tau peptides in biological samples, including blood-based samples from subjects, involving the use of a capture antibody that binds to a MTBR-tau 243 species, and a detection antibody. In some embodiments, the methods and assays include an immunodepletion step using one or more immunodepletion antibodies.
Resumen de: US20260169011A1
Provided herein are methods for providing personalized nutritional supplementation to a subject. Also provided are compositions of personalized nutritional supplementation for subjects in need thereof.
Resumen de: WO2026128544A1
The present disclosure provides compositions and methods for determining the folding of a protein of interest. The present disclosure further provides methods for determining the pathogenicity of mutations in proteins.
Resumen de: WO2026128913A1
Method are providing such as a method for detecting axon length in a neuronal cell culture that can be used for high throughput drug screening by culturing neuronal cells derived from a subject or an induced pluripotent stem cell line; imaging the neuronal cells to determine axon length; and correlating the axon length to a presence or severity of a neurological or metabolic disorder.
Resumen de: US20260169009A1
The present invention comprises a method for determining the biological age of an animal, wherein the method comprises determining the level of at least one biomarker in said animal, and wherein the at least 1 biomarker is selected from the biomarkers as listed in Table 1.
Resumen de: US20260169000A1
0000 The present invention comprises a method for determining the biological age of an animal, wherein the method comprises determining the level of at least one biomarker in said animal, wherein at least 1 biomarker is selected from the biomarkers as listed in Table 1.
Resumen de: WO2026128628A1
The present disclosure is related to non-destructive, long-term electrophysiological recording and stimulation of organoids. For example, an example device includes biocompatible material and electrodes fabricated onto the biocompatible material. The example device, through controlled buckling and microfolding, forms a pocket for an organoid.
Resumen de: US20260167636A1
The present invention relates to compounds which are suitable for imaging TDP-43 (Transactive response (TAR) DNA binding protein 43 kDa) aggregates. The compounds can be used, for example, for diagnosing a disease, disorder or abnormality associated with TDP-43 aggregates or a TDP-43 proteinopathy, such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Frontotemporal dementia (FTD) and limbic-predominant age-related TDP-43 encephalopathy (LATE).
Resumen de: US20260166125A1
Disclosed are compositions and methods for using heme and at least one PAMP and/or DAMP molecule for activating NLRP12 and/or NLRC5 and inflammatory cell death. Also provided is a screening assay for identifying NLRP12 and/or NLRC5 inhibitors and use of such inhibitors in the treating or ameliorating of NLRP12-mediated or NLRC5-mediated inflammation associated with a hemolytic disease, infectious disease, cancer, or inflammatory syndrome.
Resumen de: US20260168983A1
0000 The present invention relates to a YaxAB nanopore, a system comprising the nanopore and applications thereof. The YaxAB nanopore has a funnel-shaped three-dimensional structure that enables ultrasensitive detection of subtle changes in conformation and dynamics by sensitively monitoring current blockade variations. In addition, it induces potent electroosmotic flow with extraordinarily cation selectivity, allowing single-molecule analysis of various analytes regardless of net charge. The amino acid sequence of a monomer can be changed to regulate oligomerization and improve the purification yield, enabling one-step production of pores with diverse diameters that cannot be achieved using wild-type monomers. The tunable pore size, combined with the wide inlet and narrow outlet design, provides a broad dynamic range of analyte sizes, allowing single-molecule analysis of large-sized analytes. In addition, the invention offers a stable membrane composition, enabling single-molecule analysis with ultrahigh sensitivity and resolution for diverse applications including drug discovery and diagnostics.
Resumen de: US20260166121A1
0000 Disclosed are methods of treating hemorrhagic shock, for example hemorrhagic shock associated with traumatic injury, gastrointestinal bleeding, spontaneous hemorrhage due to hematologic disorders, uterine hemorrhage, and combinations thereof, in an individual in need thereof. The methods may comprise administering a humanin protein or an analog thereof, for example Humanin G, to the individual.
Resumen de: WO2023210585A1
The present invention provides a means for targeting a substance to motor nerve cells. Provided is a targeting agent for a motor nerve cell synapse including an antibody that can bind to an in-vesicle domain of synaptotagmin 2.
Resumen de: US20260168029A1
The present invention relates to: a biomarker for predicting the prognosis of colorectal cancer by using changes in expression level of mRNA of a HSPD1 gene or a HSP60 protein encoded by these genes; and a prognosis prediction method using same. By analyzing the expression level of the HSPD1 gene or the HSP60 protein, the prognoses of colorectal cancer patients can be predicted in clinical practice, and when analysis is carried out in combination with TNM classification, more sophisticated prediction is possible and personalized strategies can be designed.
Resumen de: US20260167928A1
Disclosed herein are methods and compositions useful in screening a compound for its effect on proteotoxicity and proteinaceous inclusions involved in neurological disease.
Nº publicación: JP2026099917A 18/06/2026
Solicitante:
アクソンニューロサイエンスエスエー
Resumen de: WO2021048619A2
The disclosure provides immunogenic peptides, compositions, means, and methods for treating Alzheimer's disease or mild cognitive impairment. The disclosure turther provides means and methods for diagnosing patients, selecting patients for treatment, and/or evaluating the efficacy of treatment for Alzheimer's disease or mild cognitive impairment
BOPI
Sede Electrónica
